Sökning: onr:"swepub:oai:DiVA.org:uu-135021" > Melphalan and predn...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06882naa a2200709 4500 | |
001 | oai:DiVA.org:uu-135021 | |
003 | SwePub | |
008 | 101203s2010 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:ff5230b1-5218-4eba-a93d-9e31032ed581 | |
009 | oai:DiVA.org:umu-36855 | |
009 | oai:DiVA.org:liu-59727 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1350212 URI |
024 | 7 | a https://doi.org/10.1182/blood-2009-08-2379742 DOI |
024 | 7 | a https://lup.lub.lu.se/record/16978712 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-368552 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-597272 URI |
040 | a (SwePub)uud (SwePub)lud (SwePub)umud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Waage, Andersu Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway,NTNU4 aut |
245 | 1 0 | a Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma |
264 | 1 | b American Society of Hematology,c 2010 |
338 | a print2 rdacarrier | |
520 | a In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Gimsing, Peteru Department of Hematology, Rigshospitalet and University of Copenhagen4 aut |
700 | 1 | a Fayers, Peteru Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway4 aut |
700 | 1 | a Abildgaard, Nielsu Department of Hematology, Odense University Hospital, Odense, Denmark4 aut |
700 | 1 | a Ahlberg, Luciau Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US4 aut0 (Swepub:liu)lucah64 |
700 | 1 | a Björkstrand, Bou Hematology Centre, Karolinska University Hospital/Huddinge, Stockholm, Sweden4 aut |
700 | 1 | a Carlson, Kristinau Uppsala universitet,Medicin,Hematologi,Department of Hematology, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)krica965 |
700 | 1 | a Forsberg, Karinu Umeå universitet,Onkologi,Norrland University Hospital4 aut0 (Swepub:umu)nonkin02 |
700 | 1 | a Dahl, Inger Marieu Department of Medicine, University Hospital Tromsø, Tromsø, Norway4 aut |
700 | 1 | a Gulbrandsen, Ninau Department of Hematology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway4 aut |
700 | 1 | a Haukas, Einaru Department of Medicine, Stavanger University Hospital, Stavanger, Norway4 aut |
700 | 1 | a Hjertner, Öyvindu Department of Hematology, St Olavs Hospital and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway4 aut |
700 | 1 | a Hjorth, Martinu Department of Hematology, Lidköping Hospital, Lidköping, Sweden4 aut |
700 | 1 | a Karlsson, Torbjörnu Uppsala universitet,Medicin,Hematologi,Department of Internal Medicine, Capio Sankt Görans Hospital, Stockholm, Sweden4 aut0 (Swepub:uu)tokar839 |
700 | 1 | a Knudsen, Lene Meldgaardu Department of Hematology, Herlev Hospital, Copenhagen, Denmark4 aut |
700 | 1 | a Nielsen, Johan Lanngu Department of Hematology, Aarhus University Hospital, Aarhus, Denmark4 aut |
700 | 1 | a Linder, Olleu Department of Medicine, Örebro University Hospital, Örebro, Sweden4 aut |
700 | 1 | a Mellqvist, Ulf-Henriku Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut |
700 | 1 | a Nesthus, Ingeridu Department of Medicine, Haukeland University Hospital, Bergen, Norway4 aut |
700 | 1 | a Rolke, Jurgenu Department of Medicine, Kristiansand Hospital, Kristiansand, Norway4 aut |
700 | 1 | a Strandberg, Mariau Department of Medicine, Sundsvalls Hospital, Sundsvall, Sweden4 aut |
700 | 1 | a Sörbo, Jon Hjalmaru Department of Medicine, Levanger Hospital, Levanger, Norway4 aut |
700 | 1 | a Wislöff, Finnu Department of Hematology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway4 aut |
700 | 1 | a Juliusson, Gunnaru Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Lund University Hospital, Lund, Sweden4 aut0 (Swepub:lu)stem-gju |
700 | 1 | a Turesson, Ingemaru Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Department of Medicine, Malmö University Hospital, Malmö, Sweden4 aut0 (Swepub:lu)medf-itu |
710 | 2 | a Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norwayb NTNU4 org |
773 | 0 | t Bloodd : American Society of Hematologyg 116:9, s. 1405-1412q 116:9<1405-1412x 0006-4971x 1528-0020 |
856 | 4 | u http://dx.doi.org/10.1182/blood-2009-08-237974y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-135021 |
856 | 4 8 | u https://doi.org/10.1182/blood-2009-08-237974 |
856 | 4 8 | u https://lup.lub.lu.se/record/1697871 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-36855 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-59727 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.